165 Apremilast, an oral phosphodiesterase-4 inhibitor, is associated with long-term (156-week) improvements in Bath Ankylosing Spondylitis Disease Activity Index Score in subjects with psoriatic arthritis: pooled results from three phase III randomised controlled trials
2015 ◽
Vol 74
(Suppl 2)
◽
pp. 350.2-351
◽
2016 ◽
Vol 75
(Suppl 2)
◽
pp. 608.1-608
2015 ◽
Vol 74
(Suppl 2)
◽
pp. 355.3-356
◽
2017 ◽
Vol 76
(6)
◽
pp. AB47
2014 ◽
Vol 70
(5)
◽
pp. AB174
◽
2016 ◽
Vol 75
(Suppl 2)
◽
pp. 597.2-598
2015 ◽
Vol 74
(Suppl 2)
◽
pp. 348.2-349
◽